Dickey–Wicker Amendment

Dickey–Wicker Amendment. First attached to the appropriations bill for the Department of Health and Human Services in 1996, this legislative provision has annually prohibited the use of federal funds for any research that creates or destroys human embryos. Named for its original sponsors, Representative Jay Dickey of Arkansas and Senator Roger Wicker of Mississippi, the amendment represents a long-standing compromise in the contentious political debate over bioethics and federal funding of science in the United States.

Background and legislative history

The amendment emerged during the political ascendancy of the Republican Revolution led by Newt Gingrich and the 104th United States Congress. It was a direct response to the first successful derivations of human embryonic stem cell lines reported by scientists at the University of Wisconsin–Madison and Johns Hopkins University in 1998, which ignited a fierce national debate. The legislative language was crafted to address ethical concerns raised by pro-life advocacy groups, including the National Right to Life Committee and the United States Conference of Catholic Bishops, who opposed the destruction of preimplantation embryos for research. The provision was signed into law by President Bill Clinton as part of the larger Balanced Budget Act and has been renewed annually through the HHS appropriations bill.

Provisions and scope

The amendment explicitly bans the allocation of National Institutes of Health funds for: 1) the creation of a human embryo or embryos for research purposes; or 2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death. This includes the process of somatic-cell nuclear transfer and other techniques involving in vitro fertilization clinics. However, it does not prohibit research using pluripotent stem cell lines derived elsewhere with private or state funds, a distinction that became central to subsequent administrative law interpretations by the NIH under directors like Harold Varmus and Elias Zerhouni.

Impact on scientific research

The restriction significantly shaped the trajectory of regenerative medicine in the U.S., creating a de facto two-tiered research system. Federally funded scientists were limited to working on the NIH Human Embryonic Stem Cell Registry of approved lines, while significant innovation in therapeutic cloning and embryoid body research often occurred in states like California (via the California Institute for Regenerative Medicine) and Massachusetts with their own funding initiatives. Major research institutions, including the Harvard Stem Cell Institute and the Stanford University School of Medicine, established entirely separate, privately funded laboratories to comply with the law. Critics, such as the American Association for the Advancement of Science, argued the policy hampered the National Cancer Institute and other agencies in the race for cures against conditions like Parkinson's disease.

Legal and political challenges

The amendment's interpretation was tested by several presidential administrations. In 2001, President George W. Bush restricted federal funding to existing stem cell lines in a policy announced from his ranch. This was reversed by an executive order from President Barack Obama in 2009, which allowed funding for research on new lines derived from leftover embryos at IVF clinics, though the underlying amendment remained in place. Legal challenges ensued, notably in the case of Sherley v. Sebelius, where the United States Court of Appeals for the District of Columbia Circuit upheld the HHS interpretation. The Alliance Defending Freedom and other groups have filed repeated lawsuits seeking stricter enforcement.

Proposed revisions and related legislation

Numerous legislative efforts have sought to modify or repeal the provision. The Stem Cell Research Enhancement Act was passed by Congress but vetoed by President Bush in 2006 and 2007. Later proposals, such as the Regenerative Medicine Act of 2021, have aimed to promote alternatives like induced pluripotent stem cell research championed by Shinya Yamanaka. The Patient Protection and Affordable Care Act debate also saw attempts to address the issue. Despite bipartisan support for updating the law, particularly following advocacy from figures like former Representative Diana DeGette and the late Senator Ted Kennedy, the amendment remains a fixture of the annual appropriations process, reflecting enduring culture war divisions.

Category:United States federal appropriations legislation Category:Bioethics in the United States Category:1996 in American law